yahoo_financeOriginal article
Johnson & Johnson's Tremfya Maintains Clinical, Endoscopic Remission at Week 144 in Crohn's Trial
Data ReadoutpositiveTremfyaPositive
AI Analysis
Summary
Johnson & Johnson's Tremfya demonstrated sustained clinical and endoscopic remission through week 144 in a Crohn's disease trial, showing positive long-term efficacy data.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Maintained clinical and endoscopic remission at week 144
Importance:6/10
Sentiment:
0.70
TremfyaCrohn's diseaseclinical remissionendoscopic remissionlong-term data
Related Companies
Read the original article
Published by yahoo_finance on October 12, 2026 8:49 PM